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2. Abstract 
Aims 
To collect updated information about pharmacological labour analgesia in Norway, especially 
systemic opioids and epidural. Evaluation of efficacy and safety with remifentanil IVPCA 
(intravenous patient-controlled analgesia) for pain relief during labour. To compare 
remifentanil IVPCAwith epidural analgesia (EDA) regarding efficacy and safety during 
labour.    
Methods 
In paper I, two national surveys identified Norwegian labour analgesia methods and changes 
during the study period (2005-2008). Paper II is a prospective, observational study of 
analgesic efficacy and safety with remifentanil IVPCA. Paper III is a prospective, randomized 
controlled trial comparing remifentanil IVPCA with EDA regarding analgesic efficacy and 
safety.  
Results 
The surveys in paper I found the frequency of EDA in Norwegian hospitals to be increasing, 
but still low (25.9%) compared to other western countries. Nitrous oxide and traditional 
systemic opioids, like pethidine, were frequently used. In paper II  remifentanil IVPCA was 
found to give satisfactory labour analgesia in more than 90% of the parturients with an 
average maximal pain reduction of 60%. Maternal oxygen desaturation and sedation were 
acceptable, and neonatal data reassuring. In paper III, a randomized controlled trial found 
remifentanil IVPCA and EDA to be comparable both regarding analgesic efficacy (pain 
reduction) and maternal satisfaction. Remifentanil IVPCA produced more maternal sedation 
and oxygen desaturation, neonatal outcome was reassuring in both groups. 
Conclusions 
The frequency of epidural labour analgesia in Norway has increased, but is still relatively low. 
Nitrous oxide and traditional systemic opioids are frequently used. The clinical practice seems 
conservative, newer short-acting opioids are seldom used for systemic labour analgesia. The 
studies on remifentanil IVPCA revealed adequate pain relief, high maternal satisfaction, and 
no serious neonatal side effects. There were no differences in analgesic efficacy, maternal 
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satisfaction, and neonatal outcome when comparing remifentanil IVPCA with EDA. 
However, remifentanil caused maternal sedation and oxygen desaturation. We recommend the 
use of IVPCA remifentanil as labour analgesia instead of traditional opioids as pethidine and 
morphine when EDA is not an option. The presence of skilled personnel and close monitoring 
is mandatory.  
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4. Abbreviations 
IV=intravenous 
IM = intramuscular 
IVPCA=intravenous patient-controlled analagesia 
IVNCA=intravenous nurse-administrated analgesia 
EDA=epidural analgesia 
PCEA=patient-controlled epidural analgesia 
CSE=combined spinal-epidural analgesia 
MA=mothers artery 
UA=umbilical artery 
UV=umbilical vein 
N2O=nitrous oxide 
LA=local anesthetic 
PDPH=post dural puncture headache 
CSD-time=context-sensitive decrement time 
FHR=fetal heart rate 
CTG=cardiotocography 
STAN=ST-segment analysis 
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5. Background 
5.1 Introduction 
Labour is known to be a very painful processs,1-3 so the ability to offer adequate pain relief is 
therefore important. Most women request some kind of pain alleviation during labour and 
delivery.4, 5  Epidural analgesia is regarded as the “gold standard“ for obstetric analgesia,3-9
but this regional technique may be unsuitable or not always possible to perform. In addition, 
many women prefer other analgesic methods for various reasons.10  Effective and safe 
alternative analgesic methods should therefore be available for parturients.5, 9, 11, 12
Nitrous oxide and parenteral opioids have long traditions as labour analgesics.9, 13-17   
Pethidine has been the most frequently used opioid for decades worldwide.5  In a survey by 
Barrat-Due and colleagues from 2005, they found that 11.7% of parturients in Norwegian 
labour units received systemic opioids, and pethidine was the most frequently used drug 
(80%).13  Another survey from the UK published in 2007, focusing availability of other 
methods than regional blocks, demonstrated that 95.5% of the responding units used 
intramuscular pethidine or diamorphine. Intravenous patient-controlled analgesia (IVPCA) 
was offered by nearly half of the responding units (49%); remifentanil was most commonly 
used (34.6%), followed by morphine (29.5%) and fentanyl (26.9%).15  Lavand’Homme and 
Roelants concluded similarly in a recent survey from Belgium; almost half of the responding 
labour units (47%) used intravenous patient-controlled analgesia when EDA was not an 
option, and remifentanil reported to be the first choice (76.5%, this included both  living 
births and intrauterine deaths).9
There has been a continuous debate as to whether the main effect of pethidine is sedative or 
analgesic, and the practice regarding pethidine seems more based on traditions than scientific 
evidence.13, 14, 18  Morphine has been recommended and used as an alternative.19 However, 
both pethidine and morphine have active metabolites that may induce side effects in the 
newborn due to residual systemic analgesia.13, 20  
The use of epidural analgesia (EDA) for labour pain has increased significantly during the last 
two decades, both internationally and in Norway.7, 9, 13, 21  In the same period, newer opioids 
with rapid onset, short half-life and no active metabolites have been introduced for labour 
analgesia. These provide new opportunities to optimize individual pain treatment for 
10 
parturients, with less cumulative effect in mother, fetus and newborn. 22-25  It has therefore 
been suggested that newer opioids, like fentanyl and remifentanil, should replace pethidine 
and morphine as parenteral labour analgesics.9, 12, 19, 26, 27  Chassard et al surveyed the use of 
intravenous opioids during childbirth in French maternity units, and found sufentanil (70%) to 
be preferred for IVPCA.28  Data from other European surveys also demonstrate use of short 
acting opiods, as discussed above. North-American labour institutions seem to have 
traditions for use of fentanyl as systemic labour analgesic.21  
Absence of 24-hours epidural service is common worldwide, and in developing countries 
neuraxial analgesia may not be an option. In a global perspective, safe and low-cost analgesia 
methods should be available for obstetric pain relief. Alternative methods to epidural 
therefore need to be explored, and research on this topic is important, aiming for effective and 
safe analgesia methods for both the mother and her baby.5  
Fig 1. Comparison of pain during labour compared to different clinical pain syndromes and 
after accidents (from Melzack 1993, with kind permission from the publisher).2
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5.2  Labour pain 
Childbirth is regarded as one of the most painful experiences during womens life 2 (Fig.1), 
and this sensation of acute pain is known to be a complex process.5, 11, 29-32  Acute labour pain 
is known as a dynamic process with intermittent uterine contractions. It is characterized by 
increasing pain as labour progresses, which normally resolves immediately after delivery.5, 32  
The neurophysiological mechanisms for labour pain includes Aį and C nerve fibre activation 
conducting nociceptive impulses from the body of the uterus to the spinal cord, mainly at 
level of the 11th and 12th thoracic dorsal roots, with some overlap into10th thoracic and first 
lumbar roots. These fibers accompany sympathetic nerve fibers in this area. During the first 
part of labour parturients feel pain from lower abdomen and the lumbar region. During second 
stage the pain is conducted via nerve fibers from the vagina and perineum (S2-S4); the 
pudendal nerve, the ilioinguinal nerve, the genitofemoral nerve and the long cutaneous nerve 
of the thigh. After entering the dorsal horns, the nociceptive impulses are conducted via 
interneurons and travel through the spinothalamic tract to the brain32-36 (Fig 2).  
In addition, the subjective experience of labour pain is influenced by multiple physiological 
and psychosocial factors. The response to sensory stimuli from the labour process, both 
during uterine contractions and cervical dilatation, is therefore extremely multidimensional.5  
It is also evident that among parturients, the experience of pain is very individual with large 
differences in pain scores. This underlines the need for recognition of individual needs, and to 
adjust pain relief according to this.2, 30  
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Fig 2. Spinal and epidural anatomy for regional obstetric analgesia (from Althaus 2005, with 
the kind permission of the publisher).21
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5.3 Labour analgesia 
Non-pharmacological methods and techniques 
With normal procedure, parturients are initially offered non-pharmacological analgesic 
methods as warm packages, warm bath (hydrotherapy), subcutanous injection of sterile water, 
acupuncture and transcutaneous electrical nerve stimulation (TENS). Aromatherapy, antenatal 
preparation and support during labour (one-to-one) are other techniques anticipated to relieve 
pain.35  
Pharmacological methods 
When labour progresses through the active phase of first stage (Fig 3), pharmacological 
methods are often offered to relieve the increasing pain, either as analgesics given 
systemically, or as an neuraxial blockade.30, 37, 38  EDA is effective and safe, and known as 
“the gold standard” method.13, 18, 39-42  The frequency of epidural- or spinal/CSE analgesia 
during childbirth has increased during the last two decades, both in Norway and other western 
countries.9, 18, 41, 43, 44  According to Gaiser, in USA the use of epidural labour analgesia was 
doubled from 1981 to 1992 (larger hospitals up to 51%), and the frequency is still 
increasing.44  Other authors describing North American practice have concluded similarly.21
In European countries, the average frequency of EDA during labour is varying; from around 
20% and up to nearly 70%.9  Barrat-Due and colleagues stated that also in Norway the 
epidural frequency was doubled from 1996 to 2002 (10.7% vs 20.6%), and the highest 
frequency reported in 2002 was 40.5%.13  
In addition to EDA, nitrous oxide and systemic opioids have long traditions used for obstetric 
analgesia. For instance, pethidine has been widely used for decades, and is a well known drug 
with low cost, and easy to administrate. However, traditional systemic opioids, such as 
pethidine and morphine, represent challenges regarding the parturient, because labour pain 
resolves immediately after delivery with risk for overdosing and opioid side effects after birth. 
These opioids are also characterized by long plasma half-life and active metabolites. Nearly 
all systemic opioids cross the placenta,45, 46 and can therefore also give side effects in the fetus 
and newborn.5, 34, 47  
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 Use of newer, short-acting opioids without active metabolites give possibilities for improved 
analgesic efficacy, and less neonatal side effects. Both fentanyl, alfentanil, sufentanil and 
remifentanil have been used.9, 15, 28  Commonly used pharmacological methods for obstetric 
analgesia are given in Table 1.  
Fig 3. The course of normal labour (from Morgan Jr GE, Mikhail MS (editors): Clinical 
Anesthesiology, second edition. Appleton & Lange, 1996. With kind permission from the 
publisher).34  
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Table 1. Pharmacological methods for pain relief during labour and delivery.7, 17, 48, 49
              
Method/technique   Efficacy  Side effects  Comment 
Regional analgesia 
EDA    Very good  Hemodynamic Anesthesiologist 
          needed  
Spinal    Very good,   Hemodynamic , As EDA, 
    rapid onset  pruritus  short duration 
           
CSE    As EDA/ spinal As spinal  As EDA 
Systemic analgesia 
Pethidine   Poor analgesia,  Sedation,  Drug and 
    but slightly better nausea   metabolites 
than placebo     accumulate in fetus 
Morphine   Poor/modest  As pethidine  Metabolites 
Fentanyl Superior to   Less nausea and Respiratory 
pethidine  sedation than  depression and  
       pethidine   desaturation 
Alfentanil   Rapid onset  Similar to fentanyl Hypotonia 
Sufentanil   Slow onset  Neonatal  Deposition of drug 
      desaturation  in placenta 
Remifentanil   Good,    Desaturation,     
    rapid onset  sedation, nausea    
Inhalation analgesia 
Nitrous oxide   Moderate  No apparant  Low cost, 
          polluter 
             
EDA=epidural analgesia 
CSE=combined spinal-epidural analgesia 
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5.4 Regional analgesia 
Epidural analgesia is today the preferred method for alleviation of pain during childbirth, and 
is demonstrated to be both effective and safe.4, 47, 50  Spinal analgesia has been used as an 
alternative regional technique to a minor, but slightly increasing degree. A combination of 
these techniques, combined spinal-epidural (CSE) analgesia, is also used; with a single shot 
spinal anesthesia producing a rapid onset of pain relief, followed by an epidural catether 
infusion with the possibility to extend analgesia if needed.7, 21, 49  There are two main 
indications for regional labour analgesia; labour pain, or pregnancy complicated by disease or 
increased risk during labour and delivery.33
Epidural analgesia 
The most effective method for control of labour pain is epidural,6, 8, 43, 47 this method is 
therefore regarded as “the gold standard”. However, this is an invasive procedure requiring an 
anaesthesiologist. Medical contraindications, including bleeding disorders,6, 51, 52 may hinder 
the use of an epidural. Alternatively, EDA may be unwanted by the parturient or technical 
impossible to perform.15, 21, 44, 53  In Norway the labour services are organized in three levels 
(level 1-3). Smaller units are served by midwifes only, and cannot offer epidural analgesia for 
their parturients (level 3). Some labour units have anaesthesiologist available, but not as 24-
hours service (level 2). Therefore, many women in labour cannot be given EDA even though 
indicated.43  
Normally EDA analgesia is started with a bolus dose of a dilute solution of a local anesthetic 
and an opioid, and maintained by continuous infusion.34, 54, 55  This epidural solution can be 
administrated as regular top-ups (bolus by midwife), continuous infusion, conventional 
patient-controlled epidural analgesia (PCEA),8, 56-59 or computer integrated PCEA.35, 60-64  The 
use of PCEA and computer integrated bolus doses have by some authors been advocated to 
optimize analgesia and prevent breakthrough pain resulting in a reduced consumption of local 
anesthetics.64
With administration of low-dose local anesthetics, as bupivacaine and ropivacaine,65, 66 in 
combination with an opioid as sufentanil or fentanyl,8 it is evident that EDA does not increase 
the frequency of Caesarean section,4, 41 but may induce longer labours, increased need for 
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oxytocin stimulation, and increased frequency of instrumental delivery.4, 40-42, 49, 67-70
Traditionally, EDA reduced the parturients mobility during childbirth. With epidural solutions 
containing low-dose local anesthetics combined with opioids, this problem is reduced 
(‘mobile epidural’).4, 64  
Potential maternal side effects include hemodynamic instability and pruritus, as well as 
nausea/vomiting, urinary retention, respiratory depression,3, 4, 58, 71-74 and impaired breast 
feeding.4, 47, 52, 70, 75-77  Epidural associated fever is still discussed, but so far without 
evidence.3, 4, 52, 78, 79  Regarding neonatal outcome the overall effect of EDA is positive.50, 70, 80
Complications to epidural may occur; accidental perforation of dura with post dural puncture 
headache being the most frequent. More serious complications as intraspinal or intravenous 
injection of epidural drugs, neurological injury and sequeles, epidural hematoma and epidural 
infection have been reported, although rare.4, 6, 39, 40, 51, 53, 81-85  Back pain is a common 
symptom after childbirth, but in a study by Loughnan and a review from the Cochrane 
Collaboration, they found no significant differences between EDA and systemic opioid 
4, 86
toms, and take immediate action when
6, 50
Spinal analgesia 
The last years spinal analgesia has also been used for pain relief during vaginal labour and 
delivery. With single-shot spinal analgesia, containing a long-acting local anesthetic and/or an 
opioid agonist, one can achieve effective analgesia with a rapid onset.49, 52  Of course, this 
method is limited by the fact that duration cannot be extended.7, 35  But when requesting 
analgesia late in labour, the spinal technique could be considered as an option, especially for 
multiparous.52, 57, 87, 88  Known maternal side effects are pruritus,64, 89 nausea/vomiting, and 
respiratory depression. Respiratory arrest has been reported with repeated doses of 
sufentanil.90  The risk for post dural puncture headache should always be considered.  
Non-reassuring FHR-changes as bradycardia has also been discussed.3, 49, 74, 87, 91-94  Thus, the 
increased risk of FHR abnormalities must be considered before using subarachnoidal injection 
of opioids.64  
analgesia.       Recommendations for safe clinical practice should be followed, and adequate
clinical observation is important to detect early symp
needed.
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Combined spinal-epidural analgesia (CSE) 
CSE is today a commonly used method for labour analgesia in many countries.3, 8, 49, 64, 95  
This method offers rapid onset of spinal analgesia by low dose of a local anesthetic or an 
opioid, or a combination of these drugs.52  The epidural catheter inserted makes it possible to 
extend analgesia, maintenance of EDA is normally achived by a solution of low-dose local 
anesthetic and an opioid agonist.3, 7, 48, 49, 60, 64, 87  Efficacy and potential side effects are the 
same as for spinal and epidural analgesia separately.87, 91, 92, 94  Theoretically, this combination 
of the two neuraxial methods should be an advantage: fast onset, reliable and high-quality 
analgesia, and high maternal satisfaction.64  But several previous studies have concluded that 
overall CSE- and epidural analgesia are comparable regarding efficacy, safety and maternal 
satisfaction.49, 87, 92, 96  Increased costs due to equipment needs and close follow up must also 
be weighed against potential positive effects by use of CSE.91, 92  
Other nerve blocks 
By use of a local anesthetic, both paracervical block and blockade of the pudendal nerve can 
be utilized as supplement to alleviate pain during labour and delivery.11, 31, 32, 50  When 
indicated, these nerve blocks are normally performed by obstetricians and midwives. 
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5.5 Systemic labour analgesia: Nitrous oxide and parenteral opioids  
In certain clinical situations regional analgesia may not be an option; it may be unavailable, 
contraindicated, imposible to perform, or not wanted by the parturient.5  For these women, an 
effective and safe analgesia alternative should be available.97
Nitrous oxide  
Nitrous oxide is the only inhalational analgesia that has reached widespread use for alleviation 
of labour pain,14, 31, 70 although more potent agents have also been used.14, 17, 31, 98  
Nitrous oxide has been used in labour since the late 1800s, and equipment for self-
administration was introduced by Minnitt in England in 1934.98, 99
The mechanism of action of nitrous oxide is thought to be an increased release of endorphin, 
dopamine, and other natural pain relievers in the brain, which modulate pain stimuli via 
descending spinal cord nerve pathways. Nitrous oxide does not completely relieve the pain of 
labour but creates “diminished pain, or a continued awareness of pain without feeling 
bothered by it”. Nitrous oxide also has an antianxiety effect, which may be helpful if laboring 
women are restless and doubt their ability to cope.98
Normally, it is given as a 50:50 mixture of oxygen and nitrous oxide. N2O has a rapid onset 
and termination of action,14, 17, 47, 98, 100  the efficacy depends on adequate N2O blood 
concentration at the peak of painful uterine contractions. This could be achieved by starting 
the inhalation as soon as the parturient first feels contraction pain, and stop inhalation after the 
peak of pain.11, 35  Of course, this technique also includes positive aspects of patient-controlled 
therapy; the patient contributes by self-administration, and by this given the possibility to 
control some of the factors alleviating pain.14, 34  N O is easy to administer, have relative 2
low costs, with tolerable side effects, and is safe for parturients and and their babies.14, 17, 70, 98, 
100-102  
Nevertheless, nitrous oxide emissions may be a risk to personnel in the working area. In a 
global perspective, it is regarded as an atmospheric polluter, and the use should therefore be 
restricted.70
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Parenteral opioids 
Use of systemic opioids has a long tradition in labour analgesia, especially pethidine has been 
widely used.5, 14, 26, 97  However, side effects and lack of evidence for analgesic efficacy have 
been the main criticism.5, 14, 26, 103-105
Other opioids with a theoretically more suitable pharmacological profile have been used as 
alternative 9, 15, 22 (Table 2). Of these, remifentanil seems to be the most promising.70, 106  
Of course, the parturient needs close monitoring because increased risk of side effects with 
such a potent opioid; skilled personnel and monitoring equipment are needed. All systemic 
administered opioids cross the placenta, with risk for neonatal respiratory depression, this 
side effect can be reversed by use of naloxone if needed.46
Both subcutanous, intramuscular and intravenous administration have been used for different 
opioids.14  Using the intravenous route, opioids can be given by midwife on demand, or as 
patient-controlled analgesia (self-administration). Women in labour receiving systemic opioid 
analgesia demonstrate great variation in respons to doses administered. This individual 
response to opioid therapy is a well known fact that could only partly be explained by genetic 
variants.1, 107, 108  Pain relief during childbirth can also be achieved by a combination of 
systemic opioids and nitrous oxide.33
As a general warning; for all pharmacological labour analgesia and anesthesia, one should be 
aware of the potential risk for pulmonary aspiration of gastric content, and “nil per os” 
policies are still discussed.101
Pethidine 
Pethidine is the most frequently used systemic opioid during the past decades 5, 11, 70  because 
it is recognized to be; a well-known analgesic, given by midwives, easy to administer, and 
associated with a low cost.5, 16, 17, 104  It was introduced into obstetric analgesia in the 1940s, 
and soon replaced morphine mainly because early studies demonstrated lower risk of 
respiratory depression compared to morphine.26  But pethidine has been demonstrated to have 
limited analgesic efficacy,20, 26, 103, 109, 110  and maternal side effects like sedation, respiratory 
depression and nausea is common.14, 17, 33, 70, 103, 104  It crosses the placenta, and active 
metabolites (norpethidine) have been found in the newborn up to 72 hours after delivery, 
risking serious neonatal side-effects like sedation, neurological dysfunction, respiration 
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depression, and delayed initiation of breastfeeding.5, 14, 17, 26, 33, 35, 80, 104, 111  Pethidine is known 
to have a narrow therapeutical window, and the use of pethidine in labour has been 
extensively discussed and criticised; giving more sedation than analgesia.5, 103, 104   
Morphine 
Morphine has been used in obstetric analgesia since the late 1800s, but its efficacy and safety 
regarding both mother and child are still discussed. Some studies have concluded with better 
pain relief by use of morphine compared to pethidine, and that morphine should be prefered 
for obstetric use.19, 26  Other authors have questioned the analgesic efficacy of morphine used 
for pain relief during labour.17, 26, 103, 112  Morphine has slow onset, compared to more lipid-
soluble compounds, but is quickly metabolized, mainly by glucuronidation, and eliminated 
from maternal circulation.14, 26  The main metabolite, morphine-3-glucuronide, has no 
analgesic activity,17, 35, 113 but has been shown to have neuroexitatory effects with high 
concentrations.113  Within doses used for obstetric analgesia, morphine has possibly less 
negative effects on the neonate compared to pethidine and its metabolites.14  However, one 
should be aware of morphine-6-glucuronide, which is an active and potent metabolite of 
morphine with longer half life.113, 114
Fentanyl 
Fentanyl is a synthetic, highly lipid soluble and protein bound opioid, with greater potency 
than morphine and pethidine, with rapid onset of action (3-4 min to peak effect) and short 
duration.14  It has no active metabolites, crosses the placenta, but has less maternal and 
neonatal side effects than pethidine.26, 115, 116  Previous studies have found fentanyl superior to 
pethidin and alfentanil regarding analgesic efficacay during labour,22, 38 and can be used as an 
alternative to EDA.38, 116  Used for second trimester genetic termination of pregnancy, 
fentanyl had satisfactory analgesic efficacy and less side effects than morphine.117  
Fentanyl can be administered intravenous by midwife (IVNCA) or as IVPCA.17, 23  It should 
be noticed that maximum dose is limited, as repeated doses increase the context-sensitive 
decrement time (the time to a 50 % reduction in blood concentration after cessation of a 
steady infusion).80  With high doses, one should be aware of possible neonatal depression.17, 
80, 95, 116, 118-120    
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Since 2005 Sørlandet Hospital in Kristiansand has used intravenous fentanyl (midwife 
administered/IVNCA) as parenteral labour analgesic (local guidelines). Based on available 
evidence, the parenteral labour analgesia procedure was changed from IV pethidine to  IV 
fentanyl.5, 104  The labour department/unit has about 2000 deliveries per year. 
Alfentanil 
Alfentanil is a synthetic lipofilic opioid, with higher protein binding than other opioids. It is 
characterized by rapid onset of action (1 min) and short duration, and with higher potency 
than morphine and pethidine. The CSD-time is shorter than for fentanyl.80  Compared to 
fentanyl, the analgesic efficacy during labour is also less,17, 22 and alfentanil seems to produce 
more neonatal neurobehavioural depression than pethidine. The use of alfentanil for systemic 
pain relief during labour is limited.80  
Sufentanil 
Sufentanil is characterized by high lipophilicity and potency, and short context-sensitive 
decrement time. The time to peak effect is slow though (4-6 min), and relatively low potency.  
The drug has been associated with risk for placental deposition and neonatal respiratory 
depression. Sufentanil is not commonly used for systemic labour analgesia, but has gained 
great popularity and is widely used for intrathecal and epidural analgesia.80
23 
Remifentanil  
Remifentanil is a potent, selective μ-opioid receptor agonist, normally around 70% protein 
bound. This synthetic opioid is characterized by a rapid onset of maximal peak effect (1.2-1.4 
minutes), and is rapidly hydrolysed by non-specific blood and tissue esterases (ester linkage) 
of unlimited capacity. This gives a constant context-sensitive half-life, with a short 
elimination half-life of approximately 3-10 minutes, and a predictable short duration and rapid 
offset of action. The elimination is independent of dose, duration of infusion and organ 
function (liver, kidneys). The metabolites have insignificant activity (1/300-1/4600 the 
potency of remifentanil).  
Theoretically, this should be the ideal opioid for systemic labour analgesia, but the optimal 
dose and administration method is still investigated. Remifentanil was first registered for 
general anaesthesia 1996.38, 80, 121  
Kan and colleagues studied serum analyses from mothers artery (MA), umbilical artery (UA) 
and umbilical vein (UV) after Caesarean section, performed in epidural anaesthesia and with 
concomitant remifentanil infusion until skin closure. They demonstrated that UV:MA and 
UA:UV ratio for remifentanil was 0.88±0.78 and 0.29±0.07, with a mean clearance of 93 
ml·kg-1·min-1.122  This indicates that remifentanil crosses placenta and is rapidly metabolised 
and distributed in the child. However, even if the drug may give maternal sedation and 
respiratory depression, there was not reported any serious incidents for mother or child. 
Nevertheless, such potential side effects require one-on-one nursing and adequate maternal 
and neonatal monitoring.80
Already in the late 1990s remifentanil was used for general anaesthesia and postoperative 
analgesia to both infants and small children. The studies reported satisfactory results 
regarding efficacy and safety.123-127  Experience and evidence from intensive care medicine 
demonstrate no accumulative effects of remifentanil used for sedation and analgesia. The drug 
seems to be safely administered to patients with reduced function of vital organs, even long 
time infusions are well tolerated without accumulative effects.114, 128  
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Remifentanil labour analgesia; Clinical studies 
Early series of case reports were based on use of remifentanil for labour because of 
contraindications to epidural; coagulation disorders, renal impairment and cardiac disease. In 
these case reports, remifentanil was evaluated to be useful, with no complications to parturient 
or newborn.129-131  
Further reports on small number of patients also concluded that remifentanil could be helpful 
to alleviate pain during normal labour.132, 133 Olufolabi and colleagues included four 
parturients in a preliminary study of remifentanil IVPCA, giving 0.25-0.5 μg·kg-1 with a lock-
out time of five minutes. The anaesthesiologist bedside was allowed to give extra doses on-
demand. The study was interrupted because of unsatisfying analgesia and maternal opioid 
related side effects. There were no neonatal side effects reported.134
Later remifentanil studies have shown promising analgesic efficacy using patient controlled 
intravenous administration.24, 135-141  Only two studies have compared remifentanil with 
epidural analgesia.142, 143   
But all these studies have limitations precluding a consistent conclusion; either few 
participants, too short observative duration, infrequent observations, or inappropriate 
registration of efficacy or side effects.24, 137, 144, 145 Different administration methods and 
dosing regimens have been proposed, but so far the optimal mode of administration and 
appropriate doses have not been found.24, 27, 135-138, 142, 144   
It has earlier been stated that remifentanil readily crosses the placenta.24, 122, 146  Maternal and 
neonatal safety issues are still discussed, especially sedation and ventilatory depression, but so 
far without conclusive evidence. The need for more studies and larger study populations have 
been emphasized.12, 27, 144
A recent observational study by D’Onofrio w
continous IV infusion, but the results from pain registrations included only a short initial 
phase.147  In another recently published randomized study by Douma and colleagues, 
comparing remifentanil with meperidine and fentanyl, remifentanil produced better analgesic 
efficacy, but the pain scores in all three groups returned towards baseline (pre-treatment 
values) late in labour.38  Remifentanil IVPCA has also been used as an alternative to EDA 
during labour of twins.148  In addition, with short duration and rapid offset of action, 
remifentanil makes it possible for the parturient to have full mobility throughout the course of 
labour.  
as promising for remifentanil given as 
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Other systemic analgesics 
Other systemic analgesics as meptazinol, nalbuphine, butorphanol, pentazocine, tramadol, 
piritramid and ketamine have also been used for pain relief during childbirth. These 
analgesics seem to be used to a limited exent so far.5, 9, 17, 31, 80, 149   
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Table 2. Main characteristics of systemic opioids commonly used for labour analgesia.17, 38, 80  
 Pro Con Comment 
Pethidine -Familiarity 
-Low cost 
-Modest analgesia 
-Active metabolites 
-Neonatal side effects (3-
5 days) 
-Long traditions used for 
labour analgesia  
-More sedative than 
analgesic 
Morphine -Rapidly cleared from 
mothers circulation 
-Modest analgesic effect -Limited evidence used 
for labour analgesia 
Fentanyl -Analgesic efficacay 
better than pethidine 
-Rapid onset 
-Various administration 
methods (IV, IM, SC, 
DERM, PO) 
-CSD time increased 
-Potential neonatal 
respiratory depression 
(dose-dependent) 
-Widely used for neuraxial 
labour analgesia 
Alfentanil -Rapid onset of action 
-Short duration 
-More neonatal depressant 
than pethidine 
-Analgesic efficacy less 
than pethidine 
-Limited use for parenteral 
labour analgesia 
-Highly proteinbound 
Sufentanil -CSD time short -Slow onset 
-Possible placental 
deposition 
-Potential neonatal 
respiratory depression 
-Limited use for parenteral 
labour analgesia 
-Commonly used for 
neuraxial labour analgesia 
Remifentanil -Rapid onset 
-Rapid degradation 
-Inactive metabolites 
-Constant CSD time 
-Analgesic efficacy 
better than pethidine and 
fentanyl 
-Maternal sedation 
-Maternal desaturation 
-Administration by 
iv.pump only 
-No accumulation 
-Rapidly metabolized in 
the neonate 
-Organ independent 
elimination (tissue and 
blood esterase)  
CSD-time=context-sensitive decrement time. 
IV=intravenous, IM=intramuscular, SC=subcutaneous, DERM=transdermal, PO=peroral. 
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5.6. Maternal satisfaction 
Maternal satisfaction related to childbirth is a complex concept, and influenced by many 
factors during the labour process.3, 5, 58  This multidimensional issue is therefore challenging 
to evaluate and measure, both in research and daily clinical practice.58  Previous studies have 
used many different methods and approaches for measurement, making it difficult to compare 
the results.150  The degree of pain relief is the main subject for most parturients, although 
other factors could influence satisfaction too; thus personal expectations, amount of support 
from caregivers, the quality of the caregiver-patient relationship, and involment in decision 
making have been demonstrated as key factors for maternal satisfaction.5  
Pain relief and satisfaction are therefore not equated, but two different dimensions to be 
focused when evaluating labour analgesia.31, 151  For example; epidural is known as the most 
effective method for labour analgesia, but a recent review from the Cochrane Collaboration 
demonstrated no significant difference in maternal satisfaction when comparing EDA to 
parenteral opioids.4  It is assumed though that both analgesic efficacy and side effects of 
analgesia will be of some importance for the parturients experience and satisfaction ratings. 
Nevertheless, inclusion of patient’s satisfaction in evaluation of obstetric analgesia has been 
emphasized.150  
5.7. Norwegian labour services 
At the time we performed our studies, the Norwegian labour services were defined in three 
levels152: Level 1 (district general- and university hospitals): More than 1500 deliveries per 
year, obstetrician on call, anaesthesiologist on call, paediatrician on call, newborn intensive 
care department. Level 2 (local hospitals): More than 400–500 deliveries per year, 
obstetrician on call, anaesthesiologist on call, paediatrician associated (not on call).  
Level 3 (midwife-led delivery unit, ‘fødestue’): More than 40 deliveries per year, only 
midwife on call (no caesarean section/vacuum/forceps deliveries, no epidural service).  
About 75% of all deliveries take place in level 1 service, 24% in level 2 and only 1% in level 
3. 
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6. Aims of the study 
The main aim was to explore current practice and propose new and better pain relief in labour. 
Our main hypothesis were: 1. Norwegian systemic labour analgesia seemes to be more based 
on traditions than evidence. 2. Newer short-acting opioids as remifentanil could possibly 
replace tratiditional opioids for IV labour analgesia. 3. There seems to be a need for improved 
and individualized pharmacological pain therapy to those parturients who cannot be given 
EDA.  
Theoretically, remifentanil have a suitable pharmacological profile for obstetric analgesia. A 
well-known opioid used for surgical anaesthesia, postoperative analgesia and intensive care 
(analgesia and sedation)114 may also be used in a new clinical setting; pain relief during 
childbirth. A main intention with our clinical studies was a transfer of existing evidence, 
clinical skills and experience from anaesthesiologists to obstetricians and midwives. By this, 
our main hypothesis could be tested, and with an opportunity to improve systemic opioid 
labour analgesia.26
The overall aims with the present thesis were:  
1) To identify changes and collect updated information about pharmacological labour 
analgesia in Norway, especially the use of systemic opioids and epidural (paper I). 
2) To evaluate the efficacy and safety of remifentanil IVPCA for pain relief during labour, 
including metabolism of remifentanil in the neonate (paper II).  
3) To compare remifentanil IVPCA with epidural analgesia regarding efficacy and safety 
during labour (paper III).   
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7. Methodological considerations 
Data from all Norwegian labour wards were collected in 2005 and 2008 in paper I. In paper II 
and III, the the participants were included consecutively for these prospective studies. The 
study behind paper II was an observational study, while paper III was based on a randomized 
controlled trial. All the participants signed a written informed consent before inclusion, and 
were allowed to withdraw any time during the study period.  
7.1. National survey of methods and drugs used for pharmacological labour analgesia, with 
monitoring of changes during a 4-years periode (paper I) 
In Norwegian hospitals, pethidine has been commonly used for decades as the preferred 
opioid for systemic labour analgesia. This practice seemed more based on traditions than 
evidence. The analgesic efficacy has been questioned, while side effects as sedation are well 
known. Morphine has been recommended and used as an alternative. In addition, N2O has 
been widely used to alleviate labour pain, either as the main therapy, or as supplement to 
other analgesics. But nitrous oxide is a known polluter, therefore environmental concerns 
have restricted the use of this inhalational analgesic. During the past two decades the 
frequency of epidural labour analgesia has increased in Norway, as in most areas of the 
Western world. The epidural frequency in our hospital, however, has stayed low compared to 
other hospitals of similar size. Based on available evidence, Sørlandet Hospital in 
Kristiansand changed the procedure for systemic labour analgesia in 2005; replacing IV 
pethidine with IV fentanyl. With this background we wanted to explore the Norewegian 
pharmacological labour analgesia services, and collect updated information to monitor 
development during the research period. We had special focus on the use of systemic opioids 
and EDA frequency.  
A questionnaire concerning obstetric analgesia was sent to all labour units in Norway 2005, in 
2008 we repeated the questionnaire to all institutions with more than 1000 childbirths per year 
(85% of all births). The questionnaire requested statistical birth reports and clinical policy 
concerning labour analgesia, and focused on pharmacological methods for pain relief during 
labour. We requested information only on living births: Number of deliveries, 
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pharmacological methods, EDA frequency, local anaesthetics and opioids for EDA, use of 
nitrous oxide, systemtic opioids, and routes and methods for systemic opioid administration.    
The questionnaire contained free text boxes to fill in relevant information, and the repeated 
questionnaire in 2008 contained some additional questions to seek more detailed information.  
7.2. Prospective observational study of remifentanil IVPCA used for labour analgesia         
(paper II) 
Parturients of ASA status I or II, primi- or multipareous, normal term singleton pregnancies, 
with regular uterine contractions, cervical dilatation larger than 2-3 cm, expected vaginal 
delivery, normal fetus in cephalic presentation, pregnancy without known complications, 
normal cardiotocographic, and normal gestation age (37-40 weeks) were included. The 
exclusion criteria were contraindications to remifentanil, pethidine given < 8 hours before 
start of remifentanil analgesia, or request for epidural analgesia.  
They received remifentanil as a stepwise IVPCA bolus dose regimen with no background 
infusion. Starting dose was 0.15 μg·kg  with increasing or decreasing dosing steps of 0.15 -1
μg·kg-1. Dosing was allowed to be adjusted every 15.minute, depending on individual 
response. No maximum dose was defined. Dose adjustments depended on VAS pain score, 
parturient’s request, registered side effects and clinical observations by the investigator. The 
calculation of pca doses was based on estimated body weight by the following formula: 
patient body height minus 100 = estimated weight (kg). Remifentanil hydrochloride (Ultiva®, 
GlaxoSmithKline) was diluted in saline to a concentration of 50 μg ·ml-1. The lockout period 
was two minutes.  
Remifentanil IVPCA was administered using a pca pump (Baxter 6060 Multi-Therapy 
infusion pump, Baxter Healthcare Corporation, Kista, Sweden) with a bolus infusion speed of 
2 ml·min-1 (100 ug min-1). The parturients were allowed to use the pump until delivery. The 
observer registered consumption of remifentanil manually, in addition to automatic 
registration in the pca pump.  
Blood samples were collected from the umbilical cord for serum concentrations of 
remifentanil and its metabolites (artery, vein).  
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7.3. Prosepective, randomized controlled clinical trial comparing remifentanil IVPCA with 
routine epidural analgesia (paper III) 
Women of physical status ASA I or II and of mixed parity were included if: normal 
pregnancy and gestagion age (37-40 weeks), single and normal sized fetus, no suspected 
fetal pathology, regular uterine contractions, cervical dilatation > 2 cm and normal 
cardiotocographic pattern. Exclusion criteria were request for epidural analgesia, use of 
pethidine within 8 hours before start, or any information of contraindications to remifentanil. 
The participants were randomized to two groups; the RA group receiving intravenous patient-
controlled analgesia with remifentanil, or the EA group using epidural analgesia with 
ropivacain and fentanyl according to the department’s routine method. The randomization 
was based on a computer generated list according to numbers, with codes kept in sealed 
envelopes until study start. 
The RA group received remifentanil hydrochloride (Ultiva®, GlaxoSmithKline) diluted in 
saline to a concentration of 50 μg ·ml-1. This solution was given as stepwise bolus doses with 
no background infusion. Starting dose was 0.15 μg·kg-1, and with increasing dose steps of 
0.15 μg·kg-1 and no maximum limit. The dose was allowed to be increased or decreased every 
15.minute according to the parturients request for dose adjustment, VAS pain score and side 
effects. The lockout period was 2 minutes. The bolus infusion speed of remifentanil was 2 
ml·min-1 (100 μg·min-1). Remifentanil IVPCA was administrated using a pca pump (Baxter 
6060 Multi-Therapy infusion pump, Baxter Healthcare Corporation, Kista, Sweden). 
Calculation of pca doses was based on estimated bodyweight by the following formula; 
patients body height minus 100 = estimated weight (kg). The remifentanil consumption was 
registered automatically in the pca pump and manually by the observer. 
Parturients randomized to EDA had an epidural catether inserted in midline at level L2-3/L3-4 
by the investigator. They received a continous epidural infusion of ropivacain 1 mg·ml-1 and 
fentanyl 2 μg·ml-1 (“walking epidural”). An initial bolus dose of 10 ml, followed by a 5 ml 
top-up after 5 min (total 15 ml), was given before start of infusion (start dose: 10 ml·hour-1). 
Midwife was thereafter allowed to adjust the infusion dose (5-15 ml·hour-1), and give rescue 
doses of 5 ml if needed. If inadequate analgesia, the anaesthesiologist controlled the epidural 
catheter and adjusted the position, or a new EDA-catheter was placed if necessary.  
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7.4. Maternal monitoring and registrations (paper II and III) 
The parturients were closely observed and monitored by anaesthesiologist, midwife and 
obstetrician. The investigator (senior anaesthesiologist) stayed in the delivery department 
during the study period, and the parturients were continuously observed by the attending 
midwife.  
Maternal heart rate (HR) and oxygen saturation (SaO2) were monitored continuously 
throughout the study period. Respiratory frequency (RR), non-invasive systolic bloodpressure 
(SBP), diastolic bloodpressure (DBP) were registered every 15.minutes. All physiological 
parameters were recorded by use of a separate monitor (Nonin 2120, Scan Med AS, 
Drammen, Norway).  
Observer sedation score was registered before start (baseline), and every 15.minute by 
investigator and attending midwife without comparison, using a five-point verbal rating scale: 
1=alert, 2=slightly drowsy, 3=drowsy, 4=very drowsy, 5=unrousable.   
Pain score collected by the anaesthesiologist was recorded before start of analgesia, and every 
15.minute. The parturient was not allowed to compare with her previous scores.  
Pain assessment was registered on a horizontal visual analogue scale (VAS) (0-100 mm; 0=no 
pain, 100=worst imaginable pain). Registrations were performed before start of analgesia 
(baseline), and every 15.minute for the first two hours. The VAS score was based on 
experienced pain the last 15 minutes period, and the parturient was not allowed to compare 
with her previous pain scores. After two hours, the VAS score was performed every 
30.minute if the patient was clinical stable. After adjustment of the dose, pain score was 
registered after 15 and 30 minutes. Before baseline registration, the patient should have 
experienced 1-2 vaginal contractions without analgesia, and thus having the best possible 
foundation to evaluate the analgesic efficacy. The VAS pain registrations were performed as 
long as the patient received pain relief, and data were collected by the investigating 
anesthesiologist. Midwifes clinical impression of the parturients level of pain were also 
monitored by the same method (VAS). Midwife and patient were not allowed to see each 
others VAS pain scores.  
Observations of nausea, vomiting and itching were also registered. 
Analgesia was stopped at time of delivery. Parturients who delivered within 30 minutes were 
not included in data analysis. If conversion from remifentanil to epidural, data collected until 
conversion were included in analysis. 
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All participants were asked to fill in a questionnaire regarding satisfaction with analgesia and 
side effects (five-point categorical scale) within 24 hours after delivery. In addition, the 
attending midwife evaluated impressions of analgesia and side effects by the same method 
(questionnaire, five-point categorical scale). Mother and midwife were not allowed to see 
each others evaluations.  
7.5. Maternal side effects and practical handling (paper II and III) 
For parturients receiving remifentanil IVPCA, supplemental oxygen (4 litersÂmin-1) was 
administered via nasal cannula if SaO <92%.2 136, 139  Remifentanil analgesia would be 
temporarly stopped if persistens of SaO2 < 92%, RR < 9 breaths·min-1, SBP < 90 mmHg or 
HR < 50 beats·min-1. When physiological parameters were normalized, pain therapy could be 
started again on a one step lower dose.  
The EA group was handled in accordance with the departments clinical routines. 
Oxytocine, metoclopramide, ephedrine and intravenous fluids were available if needed.  
Equipment and drugs for handling of hemodynamic and respiratory problems were immediate 
available (Basic Life Support).  
7.6.  Fetal/neonatal monitoring and registrations (paper II and III) 
Fetal heart rate (FHR) was continuously monitored. A combined fetal heart monitor (Stan 
S21, Neoventa Medical, Götenborg, Sweden) was used for external monitoring 
(cardiotocography, CTG) and invasive fetal monitoring (ST-analysis, STAN) as warranted for 
obstetrical indications. The FHR-tracings were analyzed by an obstetrician according to the 
department’s clinical guidelines, and remifentanil was stopped if pathological changes 
occurred; absence of accelerations, decreased variability, bradycardia, tachycardia, or late 
decelerations.  
After the study, FHR registrations were evaluated separately by two obstetricians blinded to 
analgesia method and neonatal outcome.  
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Apgar scores 1, 5, and 10 minutes after delivery were recorded, and umbilical blood gas 
analysis was performed according to standard procedures (arterial and venous pH, CO2, O2, 
BE).46  Routine paediatric examination of the neonates was undertaken within 48 hours after 
birth, pathology or complications were recorded.70  Neonatal need for naloxone and 
resuscitation were registered.46, 47, 70, 153, 154   
7.7. Umbilical blood samples and analysis (paper II and III)  
Blood gas analysis: 
Blood gas analysis were performed according to the department’s standard procedures which 
included base excess (BE) (Radiometer, ABL 520, Lillestrøm, Norway).155  Lactate was not 
measured.156
Metabolism of remifentanil in neonate: 
Blood samples for remifentanil were analyzed by Eurofins Medinet B.V, Breda, Netherlands. 
Before analysis the following procedure was performed: collected blood samples were 
immediately transferred to tubes containing citrate. Blood and citrate were mixed before the 
tubes were stored in a freezer with temperature of -18°C or lower. Dry ice was used for 
transport of the remifentanil assays to the laboratory. The assay method is based on tandem 
mass spectrometry detection (LC–MS/MS).157, 158  
35 
7.8.  Statistical analysis 
SPSS version 16.0 for Windows / PASW Statistics 18 (IBM, Armonk, NY, USA) was used 
for data analysis. Statistical analysis of continuous data was performed by summary statistics, 
independent t-test, paired t-test, and Mann-Whitney U-test. For categorical data Pearson Chi-
Square test and Fisher’s exact test were used as appropriate. Data was presented as mean (SD) 
if not other specified, P-values < 0.05 were considered statistic significant for comparison of 
groups. Mixed linear modelling (30-240 minutes) was used to analyze longitudinal data on 
maternal pain, including a linear term for time. In paper II, this also included fixed effects for 
baseline pain, parity, age, BMI, supplemental oxygen and remifentanil doses. The model takes 
into account repeated measures for each parturient, and the varying number of women still in 
labour at different time-points measured. In paper II parturients of mixed parity were 
consecutively included during a 17 months period. In paper III, the prospective power 
calculation estimated a need for 26 patients in the epidural group and 26 patients in the 
remifentanil group (SD remifentanil group=20 millimeters, SD epidural group=30 
millimeters) with a power of 80% at a significance level of 5%.136, 139  Based on excisting 
evidence, significant pain reduction (VAS) was set to minimum 20 millimeters.159  
7.9. Approvals and ethics 
The project has been approved by The Regional Ethical Committee (Western Norway 
Regional Health Authority), Statens Legemiddelverk (Norwegian Medicines Agency) and 
NSD (The Data Inspectorate) / Datatilsynet (Supervisory Authority). Unexpected or serious 
side effects were to be reported to Statens legemiddelverk (Norwegian Medicines Agency) 
(paper II and III).  
Ethical aspects have been focused throughout the study because it involves both mother and 
fetus/newborn, and the research has been performed in a special clinical setting (labour and 
delivery).  
There has been no support from - or contact with - pharmaceutical industry, and there were no 
conflicts of interest. 
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8. Summary of papers 
Paper I 
In paper I, the practice of labour analgesia in Norwegian hospitals were explored, especially 
their use of systemic opioids. During the last two decades, epidural analgesia has become “the 
gold standard” for labour pain in most Western countries. Newer short-acting opioids given 
systemically may represent an alternative for adequate pain relief without using regional 
techniques. To explore current practice in Norway, a questionnaire was sent to the head of all 
46 registered labour units in 2005. The questionnaire focused on epidural and the use of 
systemic opioids. In 2008, the same questionnaire was sent to the 19 largest units reporting 
<1000 births a year, seeking updated information. Forthy-three of the 46 original 
questionnaires were returned. An epidural frequency of 25.9% was registered. For epidural 
treatment, bupivacaine was the preferred local anaesthetic, while sufentanil was the opioid of 
choice for the majority of units. Pethidine was the most commonly used opioid for systemic 
administration (77%). A few units used morphine, only one unit used IV fentanyl.  All units 
reported nurse administration of systemic opioids. The IM route was most commonly used, 
either alone (58%) or in combination with an intravenous administration (34%). There were 
only minor changes with the repeated survey, except for one large unit, which reported a 50% 
increase in the epidural frequency. The study concludes that the frequency of epidural for 
labour analgesia is still relatively low in Norway, but seems to be increasing. Systemic 
opioids are often used instead of or as a supplement. Clinical practice seems to be 
conservative, and newer short-acting opioids are seldom used systemically.  
Paper II 
Remifentanil seems to have a suitable pharmacological profile for labour analgesia. But the 
evidence so far is limited, and the need for more studies has been emphasized. In a 
prospective, observational study we examined intravenous patient-controlled analgesia used 
as stepwise bolus doses. Primary outcomes were pain reduction and maternal satisfaction. We 
also investigated maternal and early neonatal side effects, and metabolism of remifentanil in 
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the neonate. Parturients with normal term singleton pregnancies were recruited. Starting bolus 
dose was 0.15 μg·kg-1, with increasing dose steps of 0.15 μg·kg-1 and lock-out time two 
minutes. Pain scores were recorded every 15.minute using a 100 mm visual analogue scale 
(VAS). Maternal oxygen saturation (SaO2) and heart rate (HR) were monitored continuously. 
Systolic and diastolic blood pressure, respiratory rate (RR) and maternal sedation were 
recorded every 15.minute. Supplemental oxygen was administrated if SaO2<92%. Neonatal 
data included Apgar scores, clinical examination, naloxone use, resuscitation, umbilical blood 
gases and umbilical remifentanil concentrations. Forty one parturients were enrolled, duration 
of analgesia was mean 216 (range 68-439) minutes. Pain scores (VAS) were significantly 
reduced the first 3 hours of therapy. Maximal measured pain reduction was average 60% 
compared to baseline. Doses varied between 0.15-1.05 μg·kg-1. Thirty-seven (93%) reported 
satisfaction with analgesia. Lowest SaO2 and RR were 91% and 9 ·min-1, respectively. 
Supplemental oxygen was administrated to 11 parturients (27%), the level of maternal 
sedation was moderate. Neonatal data were reassuring. The study concludes that remifentanil 
as IVPCA bolus doses gives adequate pain relief and high maternal satisfaction.  Sedation and 
ventilatory depression may occur, but no serious neonatal side effects were registered. Careful 
monitoring is mandatory.  
Paper III 
Based on the satisfactory results in paper II, we compared the analgesic efficacy and side 
effects of remifentanil IVPCA with standard epidural analgesia during labour. Thirty-nine 
parturients with normal singleton pregnancies and of mixed parity were randomized to receive 
either remifentanil IVPCA (RA group), or epidural analgesia (EA group). The epidural 
solution contained ropivacain 1 mg·ml-1 and fentanyl 2 μg·ml-1, initial infusion dose was 10 
ml·h-1. Starting bolus dose of remifentanil was 0.15 μg·kg-1, with increasing dose steps of 
0.15 μg·kg-1. Lock-out time was 2 minutes, bolus infusion speed 2 ml·min-1 (100 μg·min-1) 
and  without background infusion. Visual analogue scale (VAS) was used for pain 
assessment. Maternal heart rate, blood pressure, oxygen saturation, respiratory rate, sedation, 
nausea/vomiting, itching, satisfaction with analgesia and fetal/neonatal outcome were 
recorded. Thirty-nine parturients of mixed parity were enrolled, inclusion was stopped at this 
number because of technical problems with the IVPCA pumps (EA group 20, RA group 37). 
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Thirty-seven parturients were included in analysis. Both remifentanil and epidural reduced 
pain effectively, with no significant differences (p=0.366) between the groups during the 
study period. Pain reduction at end of first and second stage, and maximum pain reduction, 
was similar (RA/EA): 27/26mm (p=0.920), 31/29mm (p=0.909) and 61/59mm (p=0.855). 
There was no difference between the groups regarding satisfaction. One parturient receiving 
remifentanil (6%) were converted to epidural because of inadequate analgesia. Remifentanil 
produced more sedation, desaturation (SaO2<92%) and need for supplemental oxygen. Fetal 
and neonatal outcome was reassuring. Highest mean dose of remifentanil was 0.70 (0.30-
1.05) μg·kg-1. Parturients receiving epidural analgesia reported some better pain scores 
compared to remifentanil IVPCA, but all differences were non-significant.  
The study concludes that remifenanil produces effective analgesia comparable with EDA, 
with high satisfaction scores and reassuring neonatal outcome. There is a higher risk for 
sedation and desaturation, therefore close monitoring is mandatory. 
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9. General discussion 
9.1. Methodology 
Surveys 
Good clinical practice should mainly be based on updated scientific evidence and 
recommendations, but can sometimes be influenced by other factors like traditions and 
culture. If clinical recommendations and procedures are not in accordance with the available 
guidelines, changes in clinical practice should be considered. If need for updated information 
regarding current practice, a national survey is a recommended scientific approach. This 
method gives the opportunity to compare own practice with other hospitals, and to look for 
development and improved diagnostic and therapeutical options. Of course, despite standard 
questionnaires and accurate study procedures, survey results can be inaccurate and lack 
information. For example, the respondents can give different interpretations of the questions 
asked, or simply not give full and honest answers in some situations.160   
Nevertheless, a survey can be a good scientific method to identify both future research topics 
and potential key points for improvement of clinical practice. One strength of the current 
survey is non-selected information on the topics investigated, as the respondents represent the 
real population we intended to study. All registered labour units in Norway in 2005 were 
included in the survey, with a response rate of 93.5%. A limitation of the 2005-questionnaire 
was that we did not ask specifically about other neuroaxial methods than EDA, or use of 
peripheral nerve blocks. The repeated survey from 2008 contained questions about neuroaxial 
blockades (spinal and CSE analgesia). Other limitations might be lack of questions for 
detailed protocols or dosing recommendations for systemic opioids, and that the questions 
were related to living births only. 
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Prospective observational studies 
Implementation of new clinical methods and techniques should be based on scientific 
evidence. The ideal, high quality, clinical trial includes randomization, blinding, control 
group, sufficient power and trial size, and adequate size of effects  to be clinical important. In 
clinical medicine, such controlled studies can sometimes be difficult to perform, because of 
practical reasons or ethical concerns, and observational studies might be the most suitable 
design to use.46, 52  Although observational studies might be biased (for instace by selection, 
or observervation parameters), this method is important to bring scientific documentation by 
systematic continuous registration of effects and side effects, for example in a new field of 
research and practice.  
Our department has about 2000 deliveries per year. The parturients were consecutively 
included from our daily clinical practice (paper II), the results of the study should therefore be 
valid also for other hospitals, event though the number of included patients was not very high. 
To perform large and well designed studies of remifentanil labour analgesia is challenging, 
because of the resources needed, it is time consuming and occupies skilled personnel for long 
periods   (observing anaesthesiologist and midwives).  
To increase the study population, we chose an observational study design and included both 
primi- and multipareous. Even though the study was possibly underpowered to draw 
conclusions on neonatal outcome and safety, as serum concentrations of remifentanil were 
analyzed from a limited number of umbilical cords. The complex techniques and prosedures 
to secure quality of these samples were the main reasons for the limited number analyzed.  
The chosen study design  also has some other limitiations; it could be biased by selecting 
subjects positive to try systemic opioid analgesia,  previous childbirths may influence the 
parturients evaluation,  and lower the risk of obstetric intervention.  We did not have a 
systematic registration of nausea/vomiting and itching with baseline values. Finally, 
registration of end tidal CO2 could have given valuable additional ventilatory information, as 
hypoventilation could be detected earlier than by monitoring just oxygen saturation and 
respiratory rate.161
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Randomized, double blind trials 
For clinical research, randomized trials are the preferred design, and known to be the “gold 
standard” method. By this design, with a calculated number of participants to give sufficient 
power, it is possible to reveal even small differences in measured parameters. But to be of 
interest for clinicians in daily practice, such differences must be of clinical relevance. In 
addition, randomized clinical trials are normally designed for evaluation of defined end points 
(efficacy, side effects). They are usually not designed to detect infrequent side effects. 
Blinding of patient and/or investigator can be used to strengthen the results of a study. 
Nevertheless, even such well-designed studies are based on a selection of patients, and thus 
not automatically transferable to daily clinical practice. 
Our study of remifentanil IVPCA compared to EDA (paper III) was not blinded. Of course, 
this could give biased results, but we found blinding to be ethical doubtful and too 
demanding.52  As already mentioned, we might have strengthened the study by monitoring 
end tidal CO2, and collecting information about nausea/vomiting and itching before start. The 
prospective sample size calculation considered pain reduction, and did not consider side 
effects. After inclusion of 39 patients we had a technical problem with our remifentanil 
infusion pump, but as we were so near the calculated sample size, we decided to stop 
inclusion, instad of finding another pump with other technical specifications that could 
influence the results. 
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9.2. Changes in pharmacological labour analgesia in Norway, especially the use of 
parenteral opioids and epidural. 
Epidural is shown to be the most effective analgesia method for women in labour, and the 
EDA-frequency has increased markedly the last two decades in the Western world, including 
Norway. Pethidine has been the opioid of choice for systemic labour analgesia in most 
Norwegian labour wards, and this preference has been stable for  several decades, even 
though criticism have been raised; claiming that pethidine  is more sedative than analgesic, 
and therefore should not be used. Many departments also use nitrous oxide inhalation to 
alleviate labour pain, either alone or in combination with pethidine, despite the increasing 
warnings regarding pollution and environmental concerns. Several studies have shown that 
both pethidin and N2O give only modest analgesia.19, 20, 38, 98, 102, 103, 138, 141, 145   
There is obviously need for a change to offer an efficient alternative to the parturients that 
may not be able to use an epidural. Newer, short-acting systemic opioids have a more suitable 
pharmacological profile for pain relief during labour and delivery. Clinical studies have 
demonstrated analgesic efficacy, however, the maternal side effects have been a problem.    
On this background, we conducted a survey to evaluate the pharmacological methods used for 
labour analgesia in Norway. Opioids and routes of administration were specially focused.  
The results indicate that EDA was used by one-fourth of all parturients. We found that 
pethidine was the most used parenteral opioid, followed by morphine. One obstetric 
department used fentanyl and two used remifentanil in 2008. IM administration of systemic 
opioids was widely used.  
Neuraxial labour analgesia 
The frequency of EDA was found to be comparable with the results from a previous 
Norwegian study, and the frequency seems to be increasing.13, 43  Compared with many other 
Western countries the frequency is still low.3, 7, 9, 21, 44  This is surprising in a country with one 
of the world’s highest income per citizen, and with a well-developed public health care 
system. This low frequency of epidural may partly be explained by the way labour service is 
organized in Norway. Only level 1 and level 2 have resources to provide an epidural service 
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to the parturients. Level l units and the majority of level 2 units offer this as a 24 h service. In 
the level 1 units, epidurals were provided to about 30% of parturients, and for level 2 units the 
average epidural frequency was about 20%. Level 3 units (called ‘fødestuer’, midwife-led 
delivery units) have a midwife service, but without obstetrician, anaesthesiologist or 
paediatrician available.152 These units, however, represent only 1% of the annual deliveries. 
With this differentiated and decentralized labour service, it is important to have effective and 
safe pain relief alternatives. Even though EDA is regarded to be both effective and safe, not 
all women may be given this treatment. The procedure can be contraindicated, impossible to 
perform or unwanted by the parturient. Caesarean section rates were earlier thought to be 
increased by an epidural; today, there is no evidence indicating such an increase.44  However, 
as for all invasive procedures, possible negative effects have to be evaluated before starting an 
epidural.  
Sufentanil was the most commonly used opioid for EDA, especially in level 2 units. In the 
larger units (level 1), fentanyl was used as frequently as sufentanil. The results may indicate 
that the larger units have a more conservative attitude concerning epidural opioids. This may 
also reflect different opinions; some experts regarding sufentanil as a safer drug than fentanyl, 
while others concluding that the two opioids are equally safe.55, 74, 93, 162, 163  
Bupivacaine was the preferred local anaesthetic component of the epidural solution (56%), 
followed by ropivacaine (39%). One ward reported the use of PCEA.  
The design of the survey did not explore regional techniques other than EDA. Information 
collected indicated some limited use of spinal- and/or CSE analgesia, but the total number 
was small, and comparable with a previous Norwegian study.13   CSE is commonly used in 
many Western countries today, and by many thought to combine the advantages of both 
epidural- and spinal techniques. A Cochrane review in 2012 compared CSE with both high- 
and low-dose EDA for labour regarding efficacy and safety. They found CSE to have slightly 
faster onset of pain relief, but produced more itching compared to EDA. There were no 
differences in maternal satisfaction, mobility in labour, headaches, Caesarean section or 
fetal/neonatal side effects. Overall, they found little difference between the two techniques.49
In our surveys, we did not record data on peripheral nerve blocks. 
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Systemic labour analgesia: Opioids and nitrous oxide 
According to the performed surveys, systemic opioids are widely used for pain relief during 
labour. Pethidine is still the most frequently used opioid in Norway, even though side effects 
have been extensively discussed.13, 14 Several studies have concluded that other opioids have 
better analgesic effects and less side effects, and the analgesic efficacy of pethidine has thus 
been questioned.14, 20, 110  A recent Cochrane review5 on 54 studies including over 7000 
parturients evaluated parenteral opioids for maternal pain relief in labour. The review 
concluded that, parenteral opioids provided some pain relief, but for most outcomes there 
were no significant differences between the different opioids. There were no good studies on 
opioid safety, thus the assessment of safety was poor.  
In our two surveys we found that some units used morphine, and the use seemed to increase 
according to the repeated survey in 2008. Morphine has a shorter half-life and a more rapid 
plasma clearance than pethidine in pregnant women, and may thus be a better alternative. 
However, there are few studies evaluating the analgesic effect and side effects of morphine 
during labour. Both morphine and pethidine have active metabolites, nor-pethidine being the 
most worrying concerning neonatal side effects.13, 14, 17, 26, 113   
Since 2005 our hospital has replaced pethidine with IV fentanyl as the routine opioid method 
for treating labour pain. No other Norwegian hospital reported the use of fentanyl, even 
though fentanyl has been used for pain relief during labour in several other Western countries. 
It has been shown to have potent analgesic effects on labour pain and acceptable side 
effects.17, 22, 26  
Our own experience with fentanyl so far is very positive. Compared with other similar 
hospitals in Norway, the epidural frequency is low. Our experience is that we often succeed in 
controlling the labour pain by using fentanyl.17, 142  Results from the first year of fentanyl 
labour analgesia, indicate pain reduction (VAS score) and maternal satisfaction with 
analgesia, so far without reports of serious side effects (unpublished data).  
The survey indicates that the use of opioids for labour pain in Norway seems to be based more 
on traditions, than evidence-based knowledge. According to available evidence, the use of 
pethidine and morphine to parturients should be reconsidered and reduced. The frequent use 
of nitrous oxide is also questionable, and remifentanil has been demonstrated to provide better 
analgesia than nitrous oxide.145  Recent publications have demonstrated changes in the use of 
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systemic opioids in many countries. Fentanyl, alfentanil, sufentanil and remifentanil are used 
as systemic labour analgesics in several Western countries.15, 28  These newer opioids may 
provide better analgesia, but their possible side effects have to be monitored carefully, and 
further studies on safety and efficacy are needed.27, 164   
The majority of the responders used IM administration of opioids, either alone or in 
combination with IV administration. No wards on level 3 reported use of IV administration. 
Units on levels 2 and 3 more frequently used the IM route alone compared with level 1. It is 
surprising that so many labour units still use IM administration. From a pharmacological point 
of view, the IV route is preferable. It is easier to control, and titrate to optimal effect.17, 165
The use of short-acting opioids with a fast onset is preferable. Some studies have pointed out 
that opioids should be delivered as IVPCA.15, 22 This may optimize pain relief, reduce the 
total dose required and cause less side effects. However, other studies have not demonstrated 
any difference between IVPCA and nurse-administrated IV analgesia with respect to these 
issues.23 Our study demonstrates that Norwegian labour units do not offer patient-controlled 
analgesia to the parturients. Nurse-administered systemic opioids thus seem to be the most 
common method used in Norwegian labour wards. The number of patients receiving such 
analgesia varied, from 1% up to nearly half of the vaginal births (44%). Several responding 
units reported imprecise registration of labour analgesics; four units answered that they did 
not have reliable statistics on the use of systemic opioids. This is a major concern; as 
registration of such clinical data should be performed continuously. This form of 
documentation is mandatory both for medical and legal purposes.  
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Resources and health economics 
For EDA, extra resources are required compared with traditional systemic pharmacological 
methods for pain relief. Increased epidural costs are due to both the professional resources 
needed and the increased complication costs, even though the methods for estimating costs 
have been discussed.43, 52, 162, 166-169   
The use of a potent opioid as remifentanil for labour analgesia require close monitoring and 
one-to-one midwifery, by this increasing the need for resources and personell compared to the 
use of other systemic opioids. Continuous presence of a competent person during labour (a 
doula) has been demonstrated to have positive effects on the labour process per see; reducing 
the need for pharmacological analgesia as EDA, and also reducing the frequency of Caesarean 
section and instrumentanl delivery, in addition to better coping and less tension for the 
parturient.52, 170-172  Therefore, by the use of one-to-one midwifery the real total costs of 
remifentanil IVPCA labour analgesia may be lower than demonstrated by an isolated 
economical calculation.  
Conclusion 
Labour analgesia in Norway seems to be based on conservative traditions. 
Nitrous oxide is frequently used, as well as systemic use of pethidine and morphine. Newer 
opioids were very seldom used. Epidural frequency is rather low compared with other 
Western countries. Bupivacaine combined with fentanyl was the most frequent epidural 
solution used. A continuous fixed infusion was preferred, and some offer boluses given by a 
midwife. Only two hospitals had experience with newer opioids for IV labour analgesia.  
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9.3. Efficacy and safety of remifentanil IVPCA for pain relief during labour, including 
metabolism of remifentanil in the neonate.  
The analgesic efficacy of traditional systemic opioids, like pethidine and morphine, has been 
questioned, and studies of remifentanil IVPCA have demonstrated promising results regarding 
labour pain reduction. In this prospective observational study, using a stepwise IVPCA bolus 
dosing regimen, remifentanil gave an overall significant reduction in pain score during the 
whole labour period including delivery. The method was assessed as clinically effective by 
the parturients, 88% would choose the same analgesia for their next labour. The highest doses 
(>0.75 μg·kg-1) seemed to induce moderate maternal sedation and respiratory depression, and 
some nausea/vomiting, but without need for medical action. These findings are in accordance 
with comparable studies where remfentanil seems to have better analgesic efficacy than both 
pethidine and nitrous oxide, although not as effective as epidural analgesia.137, 141, 142, 145  In a 
recent randomized study by Douma et al, they found remifentanil to provide better analgesia 
than both fentanyl and pethidine.38
Dosing regimen 
In previous studies, both continuous infusion, bolus doses, or a combination of these two 
methods have been used.38, 135-137, 147  In the present studies, we used a stepwise and adjustable 
dosing regimen. We found IVPCA bolus doses, without background infusion, to be a suitable 
administration method to utilize the unique pharmacokinetic properties of remifentanil.27, 135-
139  Dose steps of 0.15 μg·kg-1 gave the possibility to titrate remifentanil to find the optimal 
dose, and individualize the pain therapy.  
Some authors have recommended lean body mass for calculating the remifentanil dose.173  
The main reason for this recommendation is the low distribution volume for remifentanil (0.3-
0.4 l/kg) which means that it is only distributed to the most active and central parts of the 
body. We therefore used a simple “lean-body mass” formula (bodyweight=body height minus 
100), to avoid overdosing, although comparable studies have used total body weight.24, 135-137, 
139  We found the real total body weight to be nearly 20% higher than estimated weight, thus 
we recommend this method for calculating remifentanil doses to avoid overdosing.  
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With this approximation, the mean dose after one hour was 0.38 (0.14) μg·kg-1, which 
increased to 0.64 (0.20) at the end of stage 1. The mean maximal dose needed was 0.70 
μg·kg-1, although three participants needed 1.05 μg·kg-1. This mean maximal dose is lower 
than Evron and colleagues found in a previous study, where the mean maximum dose was 
0.93 μg·kg-1. A similar study from Finland concluded that the effective dose was 0.4 μg·kg-1, 
but this study had a duration of only 60 minutes.137, 139  We observed large variations in dose 
between individuals. This is a well known characteristic of systemic opioids, explained by 
genetic variations and different tolerance for pain.1, 24, 25, 137, 139, 174  With continuous 
monitoring, clinical observation (midwife, anaesthesiologist), and the criteria for handling of 
side effects, our dosing regimen with no maximal dose was found to be safe. 
The time interval from end of analgesia to delivery was wide; two parturients had remifentanil 
stopped early because of conversion to epidural analgesia and later Caesarean section. For one 
parturient remifentanil was continued 3 minutes after delivery (placenta problems).  
Analgesic efficacy: Pain scores and satisfaction 
The average maximal pain reduction measured was 60% (47 millimeters) in our study 
(p<0.01). VAS pain scores were significant reduced the first 3 hours of analgesia, with a 
slight increase late in labour. This pattern in pain relief is known from previous studies.24, 135, 
139, 142  But even at very painful stages during labour, the scores were lower than baseline. The 
slow increase in pain scores cannot be explained by failed analgesia as pain scores are known 
to increase as labour progress.38  Nevertheless, at end of first (full cervical opening) and 
second stage pain scores were significantly reduced (p<0.05). Average VAS scores measured 
at these clinical stages of childbirth were 63 and 64 millimeters, respectively. The maternal 
satisfaction scores in the current study were high, and this combination with sub-optimal pain 
reduction is well known, and consistent with conclusions from other authors.135, 139, 175   
It could be argued that the average pain scores late in labour are based on a too low number of 
participants, but this is also known from other studies of remifentanil. The rate of conversion 
to epidural is low compared to other studies,24, 27, 136 and only one patient in our study 
requested conversion to epidural analgesia because of inadequate pain relief. Unfortunately, 
she did not answer the questionnaire after delivery. A recent observational study by 
D’Onofrio et al demonstrated similar pain reduction and high satisfaction scores by use of 
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continuous IV infusion of remifentanil. However, pain scores were only reported for the first 
30 minutes, and cross over to epidural was not an option if insufficient analgesia occurred.147
Maternal side effects 
Respiratory depression is a feared opioid side effect.27, 134, 137, 144, 175  By continuous 
monitoring and close clinical observation we registered no SaO2 lower than 91%, and no RR 
lower than 9 breaths·min-1. Supplemental oxygen was administered immediately when SaO2 
of 92% were observed (11/41), by this avoiding hypoxemia and giving the possibility to 
continue satisfactory analgesia. Also, because of frequent uterine contractions stimulating 
maternal ventilation, ventilatory depression seems to be self-limiting. Even with the highest 
doses of remifentanil, the respiratory data were acceptable.176-179  As remifentanil is known to 
be a potent respiratory depressant, careful monitoring of ventilation is mandatory.38   
Maternal sedation is an important side effect of IVPCA remifentanil, and different sedation 
scales have been used to assess the clinical implication. In the current study (paper II), the 
sedation scores by observer were based on a five-point verbal rating scale known to the 
midwives and anaesthesiologist involved. In this context, common understanding of key 
concepts and native language was found to be crucial. In addition, we miss validated 
international sedation scales designed especially for obstetric use. In our study observer scores 
were moderate and acceptable. One of the parturient reached a maximum score of 4 out of 5, 
but this was immediately reversed by stopping the PCA pump. All subjects could easily be 
aroused by verbal stimulation. The periods between uterine contractions present special risk 
for sedation, therefore continuous monitoring is warranted.24, 135, 137, 139, 140  Different 
approaches have been tried to reduce this problem. In a recent study remifentanil bolus doses 
were administrated during the uterine contraction pause, resulting in slightly reduced sedation 
but no improved analgesia.180
 Pulmonary aspiration and pneumonitis is a rare, but feared complication associated with 
general anesthesia to parturients. With severe drowsiness during parenteral opioid labour 
analgesia, one should be aware of the potential risk for pulmonary aspiration of gastric 
content. Although this is a rare complication, passive regurgitation might occur.5, 101  
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Very few parturients reported loss of memory, and sedation was described as a positive 
experience. To our knowledge, the positive experience of sedation during remifentanil labour 
analgesia has not been focused in previous studies. Only parturients with systematic 
registrations throughout labour were included in these analysis.  
Nausea and vomiting are well known side effects of all opioids, including remifentanil.134, 136, 
138  One third of the subjects in our population reported mild nausea or vomiting without need 
for antiemetic medication. This is consistent with the results in other studies.24, 137, 139  
Itching may be a troublesome side effect of opioids. In our study three parturients reported 
itching, but there was no need for medical treatment, which is in accordance with other 
researchers.134, 135, 137
Chest wall rigigity was not observed, although this has been reported by others regarding 
neonates.181
Fetal and neonatal monitoring 
We used continuous monitoring of fetal heart rate (FHR) throughout the study period. FHR-
changes were evaluated according to standard obstetric criteria used by the department (CTG, 
STAN). There were only minor FRH changes, as also found by others.24, 135-137   
Apgar scores were within normal range, suggesting little neonatal risk using remifentanil in 
given doses close up till delivery. One minute after delivery four neonates had an Apgar score 
< 8. The lowest registered was 6, this was a primiparous with slow labour progression and 
need for mechanical delivery help. Our results are consistent with comparable studies 
regarding Apgar scores.22, 24, 135-137, 141  
Also in accordance with similar studies, we found no significant change in umbilical blood 
gases,24, 135-137 or any effect on the babies with routine paediatric examination.24
Umbilical remifentanil concentrations  
It is known that remifentanil readily crosses the placenta.24, 122, 146  The arterial and venous 
serum concentrations detected, and the calculated ratios of remifentanil and its metabolite, 
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indicate that mean bolus doses of 0.40 μg·kg-1  close up to delivery are rapidly metabolized or 
redistributed in the neonate with no accumulation. 
We collected umbilical blood samples from 17 umbilical cords to determine remifentanil 
concentrations, including metabolite analysis. Because of initial analytical problems, a 
technical challenging procedure, and short time available after labour, we did not get valid 
samples from all the umbilical cords. But as far as we know, this is still among the largest 
such samples published so far.24, 122
Conclusion 
With the mode of administration and dosing regimen in this study, remifentanil in dose range 
0.15-1.05 μg·kg-1 gives satisfactory analgesia, with significant reduction in pain scores, and 
acceptable maternal and fetal side effects during labour and delivery. We advocate an 
adjustable IVPCA bolus dose regimen with dose steps of 0.15 μg·kg-1, and lock out time of 
two minutes.  A wide range in dose requirement necessitates close titration of dose to 
individualize analgesia as labour progress.164, 182  
Such a potent opioid may require increased resources and warrants clinical observations by 
skilled personnel, one-to-one midwifery, continuous monitoring and anaesthesiologist 
immediately available. Especially maternal sedation and ventilatory depression should be 
monitored, and liberal administration of supplemental oxygen is recommended.  
Even though remifentanil crosses the placenta, it is rapidly redistributed and metabolized and 
seemed to give minimal risk of neonatal side effects. Remifentanil can be started in low doses 
early in labour, and may be used as an alternative to regional analgesia.  
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9.4. Remifentanil IVPCA compared with epidural analgesia with ropivacain and fentanyl; 
efficacy and safety during labour.   
Epidural is widely used and the preferred method for alleviation of labour pain.182  But for the 
group of parturients who cannot receive EDA, there should be effective and safe analgesia 
alternatives.175  In the current prospective randomized, controlled study both remifentanil and 
epidural reduced pain effectively, with no overall significant differences in pain reduction 
between the groups. Despite the fact that VAS scores seemed to be some lower in the EA 
group during the period measured, there were no significant differences compared to 
remifentanil. The reduction in pain score was similar at the end of first and second stage, 
which are clinical stages of labour known to be very painful. Maximum pain reduction and 
satisfaction scores were comparable between the two treatmen groups. Maternal sedation and 
oxygen desaturation was more common in the RA group. Umbilical cord blood gas values 
tended to be some lower after remifenanil therapy, but clinical neonatal outcome was 
reassuring.  
Pain reduction and satisfaction 
Pain reduction was more pronounced initially in both groups. After 2 hours, pain scores in the 
RA group increased slightly. This pattern in pain score is well known from previous studies of 
remifentanil.24, 38, 135, 139, 142, 145  There were no significant differences in pain reduction 
between the groups at the time-points measured, or overall for the whole study period 
(p=0.366). Even though, epidural tended to be slightly more effective than remifentanil 
IVPCA. 
Our results indicate analgesic efficacy of remifentanil also during second stage of labour. 
Most previous studies have focused pain reduction during first stage.12, 136  As discussed in 
chapter 9.3; it should be underlined that higher pain scores as labour progress, can be related 
to increased uterine contraction pain, and not explained by poor pain relief.38
One could argue that our average pain scores in late phases of labour are based on too low 
number of participants. This is a well known limitation from previous remifentanil studies.38, 
136, 144
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One parturient in the RA group was converted to epidural because of inadequate analgesia, 
this is a low failure rate compared with other studies.12, 27, 38  
Regarding maternal satisfaction, 76% in the RA-group and 75% in the EDA-group reported to 
be very satisfied with analgesia. 94% in the RA-group and 90% in the EDA-group would 
choose the same labour analgesia method in the future.  
The results from our study are convincing regarding remifentanil analgesia, with even better 
analgesic efficacy than demonstrated by Volmanen and colleagues.142  The remifentanil pca 
dosing were weight-adjusted, using estimated bodyweight (formula: patient body height 
minus 100 = estimated weight, kg) as recommended.173  Based on recommentatins from 
current literature, we chose to use intermittent bolus doses with no background infusion.136, 139  
Highest mean dose was 0.70 (range 0.3-1.05) μg·kg-1, at end of first and second stage the 
doses were 0.65 and 0.38 μg·kg-1. The mean dose at 1 hour was 0.40 (range 0.15-0.60) μg·kg-
1. Some previous studies have used similar doses,24, 137, 142  others have used lower doses  and 
still demonstrated analgesic effect.136, 138, 139 Dosing levels of 0.75 μg·kg-1 or more have been 
related to a higher risk for maternal oxygen desaturation and sedation. Because of individual 
variation in opioid respons,139, 174 even doses of 0.3-0.45 μg·kg-1 could give side effects. 
Based on our body weight estimate, the maximum dose 1.05 μg·kg-1 is not higher than 
maximum doses used by others.12
Maternal side effects 
We observed oxygen desaturation (<92%) and need for supplemental oxygen in 11 parturients 
in the RA group, no patients receiving EDA needed oxygen. Respiratory frequency lower than 
9 was not registered. All parturients responded to verbal stimulation, being able to take deep 
breaths and restore normal SaO2. It should be emphasized that oxygen was given immediately 
if SaO2<92%, our protocol for handling of respiratory depression was found to be safe.12, 38
In addition, ventilatory depression seems to be self-limiting because of frequent painful 
uterine contractions, stimulating the parturients ventilation. Our results are consistent with 
several remifentanil studies.136, 138-140, 142  Volikas and colleagues did not find any desaturation 
among 50 women receiving remifentanil up to 0.5 μg·kg-1.24  We found continuous pulse 
oxymetri and close clinical observation by skilled personnel to be mandatory, and recommend 
liberal administration of supplemental oxygen. 
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Sedation observer scores were significant higher in the remifentanil group after 1 hour and 
and end of first stage. Eleven from the RA group and two from the EA group reached a score 
of 3 (drowsy) as the highest, one receiving remifentanil had a highest score of 4 (very 
drowsy). All patients in the RA group experienced sedation, compared to 55% of the EA 
group. This is in agreement with other studies.24, 135, 140, 142, 145   
Comparing of maternal sedation in different remifentanil studies is hindered by the use of 
various sedation scales. In the current study we chose to use a five-point verbal rating scale, 
this issue is further discussed in Chapter 9.3 (maternal side effects). The global sedation 
scores by parturient and attending midwife were comparable. Only one patient (EA group) 
reported sedation to be associated with discomfort. Nevertheless, the RA group had a higher 
level of sedation and more respiratory depression than parturients receiving EDA, especially 
with the highest remifentanil dosing levels. In daily clinical practice, often with limited 
personnel- and monitoring resources, we recommend that the maximum dose of 0.70 μg·kg-1
should not be exceeded regarding safety issues.  
There were some more reports of vomiting in the RA group, but the difference was not 
significant. In some previous remifentanil studies the frequency of nausea has been low,24, 137
others have concluded different.135, 136, 138, 142  
Itching was reported by three patients in the EA group, which can be explained by systemic 
absorption of fentanyl from the epidural space.69, 183  In a Cochrane review of neuraxial labour 
analgesia published in 2012, they found itching to be a possible opioid side effect, and more 
frequently associated with CSE than EDA.49
  
Fetal and neonatal side effects 
Pathological FHR changes were registered for two patients in the RA group and one in the 
EDA group, all related to obstetric problems. The results are consistent with several studies of 
remifentanil.27, 135-137, 140  Volmanen and collegues found similar FHR changes during epidural 
analgesia, but more abnormal FHR changes when receiving remifentanil.142  
In the current study neonatal data were acceptable in both groups. Umbilical base excess and 
venous pH were lower in the RA group, but only the pH value being significant different 
(p=0.043). Our results are in accordance with previous literature,24, 135-137, 139, 140  indicating 
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that remifentanil can be used until delivery without harm to the newborn. Remifentanil is 
known to cross placenta, and to be metabolized or redistributed in the neonate.122
Because of technical problems with the IVPCA pumps, we decided to stop inclusion of 
patients with a total number of 39 (EA group 20, RA group 19). This was close to the 
calculated number from the power analysis, and comparable to the previous study by 
Volmanen and colleagues regarding remifentanil and epidural.142  Most previous remifentanil 
studies have a limited number of participants,12, 24, 144  and larger studies evaluating safety and 
satisfaction has been a challenge so far.24   
Conlusion 
Epidural analgesia with ropivacain and fentanyl and remifentanil IVPCA had similar 
analgesic efficacy, and with no difference in overall satisfaction. Remifentanil produced 
significant more sedation and respiratory depression, with larger need for supplemental 
oxygen. Neonatal outcome was reassuring. Continuous close monitoring by trained personnel 
and one-to-one midwifery is mandatory, and liberal use of supplemental oxygen is 
recommended. Anesthesiologist should be immediately available. The doses should not 
exceed 0.7 μg·kg-1 with standard monitoring. Remifentanil IVPCA as a stepwise bolus dose 
regimen, with dose steps of 0.15 μg·kg-1 and lock-out time 2 min, can be used as alternative to 
epidural during labour and delivery. Remifentanil analgesia may not replace epidural, but 
could be an acceptable pain reduction method when epidural is not an option.  
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10. Main conclusions 
Compared to other western countries, the epidural frequency in Norwegian labour wards is 
low, although it has increased significantly during the last decade. Nitrous oxide and 
traditional systemic opioids, like pethidine and morphine, are often used. The clinical practice 
seems conservative, newer short-acting opioids are seldom used.  
Remifentanil administered as IVPCA gives effective pain relief, and can be used as analgesia 
method during labour and delivery. Maternal side effects, like sedation and ventilatory 
depression, were acceptable but require careful monitoring with anaesthesiologist 
immediately available. In analgesic doses, remifentanil does not give serious fetal or neonatal 
side effects, and is rapidly metabolized in the newborn.  
Both EDA and remifentanil IVPCA reduced labour pain effectively, with high maternal 
satisfaction scores for both methods. Compared to EDA, remifentanil was associated with 
increased risk for maternal sedation and oxygen desaturation, and it is therefore mandatory 
with close monitoring and anesthesiologist available. Both remifentanil IVPCA and EDA 
seems safe for the neonate.  
Based on the present study and excisting evidence, we recommend the use of IVPCA 
remifentanil as labour analgesia instead of traditional opioids as pethidine and morphine when 
EDA is not an option. 
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11. Future perspectives 
Large, randomized multicenter trials are needed regarding remifentanil IVPCA labour 
analgesia; thus administration methods, dosing regimen, analgesic efficacy, maternal side 
effects, health economic issues and, personell resources needed should be further investigated. 
Maternal side effects like sedation and oxygen desaturation should have a special focus.164, 175  
Based on previous studies and clinical experience, with close monitoring by skilled personnel 
and anesthesiologist immediately available, remifentanil can today be used in low doses 
during labour when indicated. Remifentanil seems to be beneficial for obstetric analgesia, and 
is already used in some countries.9, 15, 175, 184  Because of the unique pharmacokinetic 
properties, remifentanil has the potential to be the parenteral opioid of choice for women in 
labour.  
Even though EDA is a well established and safe procedure for labour pain, the use of spinal- 
and CSE analgesia in Norway needs to be further investigated.49
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